Literature DB >> 8272943

Predictability of operative results of cervical compression myelopathy based on preoperative computed tomographic myelography.

T Koyanagi1, K Hirabayashi, K Satomi, Y Toyama, Y Fujimura.   

Abstract

The transverse area and flattening ratio of the spinal cord were determined with preoperative computed tomographic myelography in 103 patients with cervical compression myelopathy: cervical spondylotic myelopathy (n = 44); ossification of the posterior longitudinal ligament (n = 39); and cervical disc herniation (n = 20). With these values and other clinical items (eg, age, duration of symptoms, preoperative severity), a linear model to predict postoperative recovery was attempted by multiple regression analysis. In cervical spondylotic myelopathy and ossification of the posterior longitudinal ligament, the transverse area of the spinal cord and the duration of symptoms were accepted as effective explanatory variables to predict recovery. In cervical disc herniation, regardless of the transverse area or duration, the recovery was good, and pathologic state was considered essentially different.

Entities:  

Mesh:

Year:  1993        PMID: 8272943     DOI: 10.1097/00007632-199310001-00006

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  18 in total

1.  Biomechanics of cervical laminoplasty: kinetic studies comparing different surgical techniques, temporal effects and the degree of level involvement.

Authors:  Christian M Puttlitz; Vedat Deviren; Jason A Smith; Frank S Kleinstueck; Quy N H Tran; Ralph W Thurlow; Pamela Eisele; Jeffrey C Lotz
Journal:  Eur Spine J       Date:  2004-03-06       Impact factor: 3.134

Review 2.  A review of prognostic factors for surgical outcome of ossification of the posterior longitudinal ligament of cervical spine.

Authors:  Hai Li; Lei-Sheng Jiang; Li-Yang Dai
Journal:  Eur Spine J       Date:  2008-08-14       Impact factor: 3.134

3.  Predictors of surgical outcome in cervical spondylotic myelopathy: focusing on the quantitative signal intensity.

Authors:  Jing Tao Zhang; Fan Tao Meng; Shuai Wang; Lin Feng Wang; Yong Shen
Journal:  Eur Spine J       Date:  2015-07-09       Impact factor: 3.134

Review 4.  Predictors of outcome in patients with degenerative cervical spondylotic myelopathy undergoing surgical treatment: results of a systematic review.

Authors:  Lindsay A Tetreault; Alina Karpova; Michael G Fehlings
Journal:  Eur Spine J       Date:  2013-02-06       Impact factor: 3.134

5.  Clinical significance of cerebrospinal fluid nitric oxide concentrations in degenerative cervical and lumbar diseases.

Authors:  Hiroshi Denda; Shinji Kimura; Akiyoshi Yamazaki; Noboru Hosaka; Yuichi Takano; Kenji Imura; Yoichi Yajiri; Naoto Endo
Journal:  Eur Spine J       Date:  2010-12-29       Impact factor: 3.134

6.  Cervical spondylotic myelopathy: pathophysiology, clinical presentation, and treatment.

Authors:  Darren R Lebl; Alex Hughes; Frank P Cammisa; Patrick F O'Leary
Journal:  HSS J       Date:  2011-06-22

7.  Prognostic factors that affect the surgical outcome of the laminoplasty in cervical spondylotic myelopathy.

Authors:  Jae-Sung Ahn; June-Kyu Lee; Bo-Kun Kim
Journal:  Clin Orthop Surg       Date:  2010-05-04

8.  Risk factors for poor outcome of surgery for cervical spondylotic myelopathy.

Authors:  J T Zhang; L F Wang; S Wang; J Li; Y Shen
Journal:  Spinal Cord       Date:  2016-05-03       Impact factor: 2.772

Review 9.  Does the type of T2-weighted hyperintensity influence surgical outcome in patients with cervical spondylotic myelopathy? A review.

Authors:  Aditya Vedantam; Vedantam Rajshekhar
Journal:  Eur Spine J       Date:  2012-08-25       Impact factor: 3.134

10.  Presymptomatic spondylotic cervical myelopathy: an updated predictive model.

Authors:  Josef Bednarik; Zdenek Kadanka; Ladislav Dusek; Milos Kerkovsky; Stanislav Vohanka; Oldrich Novotny; Igor Urbanek; Dagmar Kratochvilova
Journal:  Eur Spine J       Date:  2008-01-12       Impact factor: 3.134

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.